Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Symptoms, Functioning, and Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab: Updated Patient-Reported Outcomes from the Phase 1/2 MonumenTAL-1 Study

Blood (2023) 142 (Supplement 1): 6711.

https://doi.org/10.1182/blood-2023-189151

Published: 2023

Journal Articles

Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study

Andrzej J Jakubowiak, Sebastien Anguille, Lionel Karlin, Ajai Chari, Carolina Schinke, Leo Rasche, Jesus San-Miguel, Michela Campagna, Brandi W Hilder, Tara J Masterson, Xiang Qin, Thomas Renaud, Jaszianne Tolbert, Deeksha Vishwamitra, Sheri Skerget, Philippe Moreau

Blood (2023) 142 (Supplement 1): 3377.

https://doi.org/10.1182/blood-2023-187242

Published: 2023

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1

Blood (2022) 140 (Supplement 1): 4447–4449.

https://doi.org/10.1182/blood-2022-162555

Published: 2022

Journal Articles

MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy

Yaël C. Cohen, Philippe Moreau, Jaszianne Tolbert, Xiang Qin, Xuewen Ma, Diego Vieyra, Angelique Langlois, Christelle Courtoux, William Terry, Lixia Pei, Christoph Heuck, Peter Voorhees

Blood (2022) 140 (Supplement 1): 4418–4419.

https://doi.org/10.1182/blood-2022-162733

Published: 2022

Journal Articles

Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in Patients with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius

Vaishali Sanchorawala, Michael Rosenzweig, Christopher Pericone, Sandra Y. Vasey, Xiang Qin, Sonja Marie Kotoulek, Bart Vandael, Joana Duran, Samer Khaled, NamPhuong Tran, Efstathios Kastritis

Blood (2022) 140 (Supplement 1): 10163–10164.

https://doi.org/10.1182/blood-2022-163615

Published: 2022

Journal Articles

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Blood (2022) 140 (Supplement 1): 384–387.

https://doi.org/10.1182/blood-2022-159707

Published: 2022

Journal Articles

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Blood (2021) 138 (Supplement 1): 159.

https://doi.org/10.1182/blood-2021-146820

Published: 2021

Journal Articles

Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda

Blood (2020) 136 (Supplement 1): 48–50.

https://doi.org/10.1182/blood-2020-137582

Published: 2020

Journal Articles

Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda

Monique C. Minnema, Angela Dispenzieri, MD, Giampaolo Merlini, MD, Raymond L. Comenzo, MD, Efstathios Kastritis, MD, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM, Martha Grogan, MD, Ronald Witteles, MD, Frederick L. Ruberg, MD, Mathew S. Maurer, MD, NamPhuong Tran, MD, Xiang Qin, MD PhD, Sandra Y. Vasey, MSc, Brenda Tromp, MSc, Brendan M. Weiss, MD, Jessica Vermeulen, MD PhD, Arnaud Jaccard, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139754

Published: 2020

Journal Articles

Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-136150

Published: 2020

Journal Articles

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Blood (2020) 136 (Supplement 1): 37–40.

https://doi.org/10.1182/blood-2020-139438

Published: 2020

Journal Articles

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Blood (2020) 136 (1): 71–80.

https://doi.org/10.1182/blood.2019004460

Published: 2020

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor

Katja C. Weisel, MD, Pieter Sonneveld, Maria-Victoria Mateos, Vania T.M. Hungria, MD PhD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Jane Estell, FRACP, Wolney G Barreto, Paolo Corradini, Chang-Ki Min, MD PhD, Eva Medvedova, MD, Maria Krevvata, PhD, Sonali Trivedi, Xiang Qin, Huiling Pei, PhD, Jon Ukropec, PhD, Rachel Kobos, MD, Ming Qi, MD PhD, Ajay K Nooka, MDMPH

Blood (2019) 134 (Supplement_1): 3192.

https://doi.org/10.1182/blood-2019-123527

Published: 2019

Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Blood (2019) 134 (Supplement_1): 1865.

https://doi.org/10.1182/blood-2019-122765

Published: 2019

Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

Blood (2019) 134 (Supplement_1): 1906.

https://doi.org/10.1182/blood-2019-122501

Published: 2019

Journal Articles

Identification of Individualized Minimal Residual Disease in Acute Myeloid Leukemia By Flow Cytometry and Its Application of Prognostic Significance

Jing-Ni Sui, Qiu-Sheng Chen, Yun-Xiang Zhang, Yan Sheng, Jing Wu, Jun-Min Li, Jiong Hu, MD, Xiang-Qin Weng, Bing Chen, MD PhD

Blood (2018) 132 (Supplement 1): 1522.

https://doi.org/10.1182/blood-2018-99-112367

Published: 2018

Journal Articles

Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies

Blood (2018) 132 (Supplement 1): 3288.

https://doi.org/10.1182/blood-2018-99-112669

Published: 2018

Journal Articles

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor

Maria-Victoria Mateos, MD PhD, Pieter Sonneveld, MD PhD, Vania T. M. Hungria, MD PhD, Ajay K Nooka, MD MPH, Jane Estell, FRACP, Wolney G Barreto, Paolo Corradini, MD, Chang-Ki Min, MD PhD, Eva Medvedova, MD, Katja Weisel, MD, Christopher Chiu, PhD, Jordan M. Schecter, Himal Amin, Xiang Qin, Ming Qi, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2018) 132 (Supplement 1): 3270.

https://doi.org/10.1182/blood-2018-99-112554

Published: 2018

Journal Articles

Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor

Hervé Avet-Loiseau, MD PhD, Jesus F San-Miguel, MD PhD, Tineke Casneuf, PhD, Shinsuke Iida, MD PhD, Sagar Lonial, MD, Saad Z. Usmani, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Philippe Moreau, Torben Plesner, MD DSc, Katja Weisel, MD, Jon Ukropec, PhD, Linda Okonkwo, Sonali Trivedi, Christopher Joseph Velas, BS, Xiang Qin, Ming Qi, MD PhD, Christopher Chiu, PhD, Nizar Bahlis, MD

Blood (2018) 132 (Supplement 1): 3272.

https://doi.org/10.1182/blood-2018-99-113177

Published: 2018

Journal Articles

Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Nizar Bahlis, MD, Meletios A Dimopoulos, MD, Darrell J White, MD, Lotfi Benboubker, MD, Gordon Cook, Merav Leiba, P. Joy Ho, Kihyun Kim, MD PhD, Naoki Takezako, MD PhD, Philippe Moreau, Maria Krevvata, PhD, Christopher Chiu, PhD, Xiang Qin, Linda Okonkwo, Sonali Trivedi, Ming Qi, MD PhD, Jesus F San-Miguel, MD PhD

Blood (2018) 132 (Supplement 1): 1996.

https://doi.org/10.1182/blood-2018-99-112697

Published: 2018

NARROW

Symptoms, Functioning, and Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab: Updated Patient-Reported Outcomes from the Phase 1/2 MonumenTAL-1 Study

Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1

MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy

Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in Patients with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda

Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

Identification of Individualized Minimal Residual Disease in Acute Myeloid Leukemia By Flow Cytometry and Its Application of Prognostic Significance

Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor

Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor

Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only